HAVCR1P1: A Promising Drug Target and Biomarker (G100101266)

Target Name: HAVCR1P1

NCBI ID: G100101266

HAVCR1P1

Other Name(s): Hepatitis A virus cellular receptor 1 pseudogene 1 | hepatitis A virus cellular receptor 1 pseudogene 1

HAVCR1P1: A Promising Drug Target and Biomarker

Introduction:

In recent years, the search for novel drug targets and biomarkers in the field of medicine has gained significant momentum. These players hold immense potential in unraveling disease mechanisms, designing targeted therapies, and enabling precision medicine. One such promising candidate that has emerged is HAVCR1P1. This article explores HAVCR1P1 as a drug target and biomarker, shedding light on its significance and potential in the field of medicine.

What is HAVCR1P1?

HAVCR1P1, also known as Kidney Injury Molecule-1 (KIM-1), is a transmembrane glycoprotein that was initially identified as an epithelial cell adhesion molecule. It is primarily expressed in the proximal tubular cells of the kidney, with its expression significantly upregulated in response to renal injury. HAVCR1P1 has since been found to be expressed in multiple other tissues, such as the urinary tract, respiratory tract, and liver. This widespread expression pattern suggests that HAVCR1P1 may play crucial roles beyond kidney injury.

HAVCR1P1 as a Drug Target:

The overexpression of HAVCR1P1 during renal injury has made it an appealing drug target in various kidney pathologies. By targeting and modulating HAVCR1P1, its role in kidney injury and repair processes can be investigated more comprehensively, ultimately leading to the development of targeted therapeutics. Several studies have already shown promising outcomes when targeting HAVCR1P1. For instance, a recent study demonstrated that blocking HAVCR1P1 in a murine model of kidney fibrosis reduced fibrotic markers and improved renal function. These results highlight the potential of HAVCR1P1 as a drug target in combating various renal diseases.

Furthermore, the expression of HAVCR1P1 in non-renal tissues opens up opportunities for targeting it in conditions beyond kidney-related disorders. For example, HAVCR1P1 has been found to be upregulated in certain cancers, including clear cell renal cell carcinoma (ccRCC) and lung cancer. Targeting HAVCR1P1 in these malignancies holds promise for a novel therapeutic approach. Preliminary studies have shown encouraging results, including the inhibition of tumor growth and improved survival rates in animal models.

HAVCR1P1 as a Biomarker:

Biomarkers play a crucial role in disease diagnosis, prognosis, and monitoring treatment response. HAVCR1P1 has emerged as a potential biomarker due to its specific expression patterns in certain disease conditions. In renal injury, HAVCR1P1 levels in urine have shown a strong correlation with the severity and progression of kidney damage. Its levels can be easily measured using non-invasive techniques, making it a promising diagnostic tool.

In addition to renal injury, HAVCR1P1 has also shown promise as a biomarker in various cancers. In ccRCC, high levels of HAVCR1P1 have been associated with poor prognosis and increased tumor aggressiveness. By quantifying HAVCR1P1 expression, clinicians can potentially identify patients at higher risk and tailor treatments accordingly. Furthermore, HAVCR1P1 has demonstrated potential as a predictive biomarker for immunotherapy response in lung cancer. Patients with higher HAVCR1P1 expression have shown improved response rates to immune checkpoint inhibitors, suggesting that HAVCR1P1 may serve as a valuable tool for personalized treatment selection.

Conclusion:

HAVCR1P1, also known as KIM-1, is a promising drug target and biomarker that holds immense potential in various disease conditions. Its specific expression patterns in renal injury and cancer make it an appealing target for therapeutic intervention and diagnostic purposes. Further research and development in this field will likely provide a deeper understanding of HAVCR1P1's role in disease pathogenesis and enable more effective treatment strategies. As we venture into an era of personalized medicine, HAVCR1P1 is set to play a crucial role in revolutionizing disease management and improving patient outcomes.

Protein Name: Hepatitis A Virus Cellular Receptor 1 Pseudogene 1

The "HAVCR1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HAVCR1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets